Advertisement

PROC

Procaps Group S.A.

Healthcare · USD

Set alert

Price alert · PROC

All alert types
1.01 USD 0.00 0.00%
As of Mar 12, 2026
1.01 Day range 1.01
0.50 52-week range 4.95
YTD
0.00%
1 year
0.00%
Open
1.01
Prev close
1.01
Mkt cap
297.86M
Vol
652.30K
Avg vol
98.16K
EPS
0.51
P/E
5.18
Div yield
0.00%
More statistics
Low
1.01
High
1.01
Forward P/E
9.78
Beta
0.17
Short ratio
1.08
Inst. own
2.93%
Dividend
0.00
Ex-div date
Earnings
Dec 24, 2024
50-d avg
1.76
200-d avg
2.30
1y target
0.00

2Y chart

Chart tools
Interval

Chart is warming up

The two-year price history for PROC has not been loaded yet. Try again in a moment.

Key statistics

Market cap
297.86M
Enterprise value
525.07M
Trailing P/E
5.18
Forward P/E
9.78
PEG ratio
0.00
Price / sales
0.72
Price / book
6.77
EPS (TTM)
0.51
Beta
0.17
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
12.61%
Revenue (TTM)
414.10M
Revenue growth
7.30%
Free cash flow
-12.18M
Total cash
17.56M
Total debt
289.92M
Return on equity
373.70%
Shares outstanding
112.82M
Short % of float
0.00%
50-day average
1.76
200-day average
2.30

Analyst view

Consensus: hold

Hold
Price target (mean) 0.00
Ratings (0m) 1 0 buy · 1 hold · 0 sell
  • Strong buy0
  • Buy0
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Dec 24, 2024

Expected Dec 24, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
PROC Revenue — quarterly 118.41M
2019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 2023
PROC Net income — quarterly 8.19M
2019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 2023
PROC EPS — quarterly 0.08
2019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 2023

Earnings

PROC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 24, 2024Sep 1, 20240.00———
Oct 1, 2024Jun 1, 20240.00———
Jul 1, 2024Mar 1, 20240.00———
May 10, 2024Dec 1, 20230.09———
Sep 5, 2023Jun 1, 20230.060.27+0.21+350.00%
Jun 5, 2023Mar 1, 2023-0.040.07+0.11+275.00%

Upgrades / downgrades

PROC analyst upgrades and downgrades
DateFirmActionFromTo
Sep 6, 2023Brookline CapitaldownBuyHold

About Procaps Group S.A.

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Luxembourg

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on PROC — it syncs with the Stock Master app.

Institution ownership

PROC institution ownership
Holder% heldSharesValueReported
Exome Asset Management LLC 0.11%126,901335.02KSep 29, 2024
Geode Capital Management, LLC0.03%28,93876.40KSep 29, 2024
Activest Wealth Management0.01%10,00026.40KSep 29, 2024
Pineridge Advisors LLC 0.00%250660Sep 29, 2024
Morgan Stanley0.00%100264Sep 29, 2024

Fund ownership

PROC fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.03%28,93876.40KOct 30, 2024
SPDR Portfolio Emerging Markets ETF0.00%150396Sep 29, 2024
Advertisement